Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR Updates Biosimilar Position Statement

Keri Losavio  |  April 4, 2018

In March, the ACR released a white paper designed primarily to help rheumatologists and rheumatology health professionals gain an understanding of biosimilars.1 This research-based education piece examines the scientific, economic and prescribing issues related to the use of biosimilars. Now, the ACR has released an update to its official position statement on the use of biosimilar therapies for rheumatology patients that further addresses extrapolation and emphasizes the importance of rigorous post-market surveillance as part of the approval process. The position statement will mainly be used to share the ACR’s perspective and discuss the various issues with external stakeholders for the benefit of the rheumatology subspecialty.

The previous position statement on biosimilars was updated in May 2016 when just one biosimilar therapy had been approved for the treatment of a rheumatic disease. The FDA has since approved five more biosimilars to treat various rheumatic diseases and issued guidance documents that provide more details on how biosimilars will be implemented in the U.S.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“With the regulatory landscape rapidly changing, we felt now was an appropriate time to revisit our 2016 statement to ensure it outlines all aspects of biosimilar adoption we would like to see addressed as these drugs become available on the market,” says ACR President David Daikh, MD, PhD.

The Position Statement
The majority of provisions outlined in the 2016 statement remained unchanged, but the new statement includes expanded views on the use of extrapolation during biosimilar approvals. Extrapolation would allow the FDA to simultaneously approve a biosimilar for all indications of its reference drug instead of requiring individual clinical studies for each indication. The position statement recommends that extrapolation be pursued with caution, with a contingency that regulatory agencies and manufacturers work with clinical experts without conflicts of interest to identify a minimum slate of disease states in which biosimilars should be tested before extrapolation to additional indications is granted.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The statement makes clear that the decision to substitute a biosimilar product for a reference drug should be made only by the prescribing provider: “Providers must retain the right to write ‘dispense as written’ for all prescriptions, including biologics.”

To address safety concerns, the statement reinforces the white paper’s call for postmarketing surveillance studies in children, as well as adults. It also states that the Best Pharmaceuticals for Children Act (BPCA), which reauthorizes the pediatric studies provision of FDA Modernization and Accountability Act to improve safety and efficacy of pharmaceuticals for children, should apply to biosimilars.

Looking Forward
As the white paper concludes, “Communication between providers, pharmacists and patients will be critical to alleviate anxiety and reduce skepticism regarding the use of these newly available agents. We remain optimistic that the use of biosimilars will improve patient access to biologic agents, allowing continued delivery of high-quality healthcare to be realized at a lower cost to the individual patient.”

Rheumatology leaders hope to see some of the concerns and principals outlined in the position statement addressed by the FDA and regulatory agencies moving forward.

With the release of the position statement, Dr. Daikh adds, “As the FDA moves to bring additional biosimilar therapies to market, we will continue to push for policies that will give providers the data they need to be confident that biosimilars are safe, effective options for them to use when deemed clinically appropriate.”


Keri Losavio is the staff editor of The Rheumatologist, ACR@Work and eNewsRheum.

Reference

  1. Bridges SL Jr., White DW, Worthing AB, et al. The science behind biosimilars: Entering a new era of biologic therapy. Arthritis Rheumatol. 2018 Mar;70(3):334–344.

Page: 1 2 | Multi-Page
Share: 

Filed under:Biologics/DMARDsDrug Updates Tagged with:position statement

Related Articles

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    Right: The small molecule structure of aspirin (21 molecules). Left: A monoclonal antibody made up of 10,000–20,000 molecules. DNA Illustrations / Science Source As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    paulista/shutterstock.com The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    Biosimilars are much bigger and more complex on the molecular level than small- molecule drugs. On the right is the small-molecule structure of aspirin (21 molecules). On the left is a monoclonal antibody made up of 10,000–20,000 molecules. The various biosimilar drugs depicted include monoclonal antibodies, scFv, Fab, and scFab, whereas the small-molecule drugs are…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences